Gilead Sciences Inc. said it has begun clinical trials of a drug designed to treat genital warts associated with the AIDS virus.
The study will evaluate the safety and potential efficacy of its GS 504 drug when applied once-daily to genital warts caused by the human papillomavirus in patients with HIV infection.
